In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

NCT02489266 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: AKTi-treated TIL
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Aldesleukin

Sponsor

National Cancer Institute (NCI)